CrossrefInfokarte
Real-world safety profile of spesolimab in generalized pustular psoriasis: expanded access programmes in Japan, China and Argentina
British Journal of Dermatology · 2026-09-06
DOI: 10.1093/bjd/ljag338 ↗Abstract
Prior to the approval of spesolimab as the first treatment for generalized pustular psoriasis (GPP), it was made available to patients via expanded access programmes in Japan, China and Argentina. As a secondary objective, the safety and tolerability of spesolimab was evaluated in a real-world population of patients with GPP.
EUVIMED